Maravai LifeSciences (MRVI): Price and Financial Metrics

Maravai LifeSciences (MRVI): $13.76

0.43 (+3.23%)

POWR Rating

Component Grades








Add MRVI to Watchlist
Sign Up

Industry: Biotech




#138 of 381

in industry

MRVI Price/Volume Stats

Current price $13.76 52-week high $33.42
Prev. close $13.33 52-week low $11.59
Day low $13.25 Volume 2,964,600
Day high $13.95 Avg. volume 2,031,135
50-day MA $13.59 Dividend yield N/A
200-day MA $16.02 Market Cap 3.45B

MRVI Stock Price Chart Interactive Chart >


  • MRVI scores best on the Quality dimension, with a Quality rank ahead of 90.55% of US stocks.
  • MRVI's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • MRVI ranks lowest in Growth; there it ranks in the 0th percentile.

MRVI Stock Summary

  • MARAVAI LIFESCIENCES HOLDINGS INC's stock had its IPO on November 20, 2020, making it an older stock than merely 11.68% of US equities in our set.
  • With a price/sales ratio of 4.69, MARAVAI LIFESCIENCES HOLDINGS INC has a higher such ratio than 77.65% of stocks in our set.
  • As for revenue growth, note that MRVI's revenue has grown -19.84% over the past 12 months; that beats the revenue growth of only 11.46% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to MARAVAI LIFESCIENCES HOLDINGS INC, a group of peers worth examining would be CLS, LPRO, UTRS, OPEN, and STIM.
  • MRVI's SEC filings can be seen here. And to visit MARAVAI LIFESCIENCES HOLDINGS INC's official web site, go to

MRVI Valuation Summary

  • MRVI's price/sales ratio is 4.8; this is 118.18% higher than that of the median Healthcare stock.
  • Over the past 30 months, MRVI's price/earnings ratio has gone up 1744.1.

Below are key valuation metrics over time for MRVI.

Stock Date P/S P/B P/E EV/EBIT
MRVI 2023-05-23 4.8 6.6 22.3 15.1
MRVI 2023-05-22 4.8 6.5 22.3 15.1
MRVI 2023-05-19 4.7 6.4 21.9 14.8
MRVI 2023-05-18 4.5 6.1 20.9 14.1
MRVI 2023-05-17 4.5 6.2 21.0 14.2
MRVI 2023-05-16 4.7 6.4 21.9 14.9

MRVI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRVI has a Quality Grade of C, ranking ahead of 71.9% of graded US stocks.
  • MRVI's asset turnover comes in at 0.307 -- ranking 150th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MRVI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.307 0.72 0.155

MRVI Price Target

For more insight on analysts targets of MRVI, see our MRVI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $49.33 Average Broker Recommendation 1.22 (Strong Buy)

Maravai LifeSciences (MRVI) Company Bio

Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.

MRVI Latest News Stream

Event/Time News Detail
Loading, please wait...

MRVI Latest Social Stream

Loading social stream, please wait...

View Full MRVI Social Stream

Latest MRVI News From Around the Web

Below are the latest news stories about MARAVAI LIFESCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate MRVI as an investment opportunity.

TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion

SAN DIEGO, May 24, 2023--TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion

Yahoo | May 24, 2023

Q1 2023 Maravai LifeSciences Holdings Inc Earnings Call

Q1 2023 Maravai LifeSciences Holdings Inc Earnings Call

Yahoo | May 9, 2023

TriLink BioTechnologies Introduces Latest mRNA Capping Technology: CleanCap® M6 analog

Newest cap analog product improves mRNA potency with greater protein expression, offers time and cost savings, and streamlines manufacturing to drive critical therapeutic and vaccine developmentSAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 . The latest CleanCap analog is expected to help developers and researche

Yahoo | May 9, 2023

Maravai LifeSciences (MRVI) Q1 2023 Earnings Call Transcript

Deb Hart, head of investor relations, you may begin your conference. Trey Martin, president of our biologic safety testing; Drew Burch, executive vice president, nucleic acid products; and Becky Buzzeo, our chief commercial officer, will join the call for the question-and-answer session following the prepared remarks.

Yahoo | May 9, 2023

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 8, 2023

Read More 'MRVI' Stories Here

MRVI Price Returns

1-mo -4.91%
3-mo -11.62%
6-mo 3.46%
1-year -56.96%
3-year N/A
5-year N/A
YTD -3.84%
2022 -65.85%
2021 49.38%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!